SOTA’s Dental Imaging Software Gets Pearl’s AI Pathology Detection Capabilities

Pearl and SOTA have partnered to offer native support for Pearl’s industry-leading, FDA-cleared radiologic AI solution Second Opinion® within the SOTA Cloud® software platform. SOTA Cloud® will be the first dental imaging software in the United States to offer a fully-integrated clinical AI feature set.

Native support for Pearl’s chairside AI within SOTA’s cloud-based imaging interface means that, for the first time, dentists in the United States can conveniently capture, display, and perform AI-assisted clinical evaluation of dental radiographs within a single software platform.

“Together with SOTA, we are pushing the envelope of dental imaging further toward a fully AI-powered dental future,” said Ophir Tanz, Pearl’s founder and CEO. “AI will be a basic utility in dentistry and we see obvious advantages to making that utility an integral feature of the tools that dentists are already using. Through this partnership, dentists using SOTA Cloud® can seamlessly access Pearl’s AI capabilities to obtain better, more consistent insights from patient imagery and present cases to patients more effectively –– leading to better outcomes, a higher standard of care and more productive patient communication.”

Pearl’s Second Opinion® is a clinical AI system cleared for use as a patient-facing radiologic aid to dentists in over 90 countries. With native Second Opinion® integration, dental practices using SOTA Cloud® –– the robust cloud-based dental imaging software which SOTA introduced last year to complement its line of state-of-the-art intraoral cameras and X-ray image sensors –– can view automatic AI detections of most conditions commonly found in dental X-rays.

“Understanding the needs of clinicians and ensuring that dentists are able to focus solely on providing the best possible patient care has always been the top priority when developing our software,” said SOTA founder and president Brian Kim. “Our partnership with Pearl speaks directly to that focus by giving practices using SOTA Cloud® push-button access to the most innovative AI technology available for streamlined patient communication and improved image-based diagnostic evaluations.”

To register for SOTA Cloud® with fully-integrated AI capabilities, visit: https://info.sotaimaging.com/sotaxpearlpartnership

To learn more about Pearl’s Second Opinion®, visit: www.hellopearl.com/products/second-opinion.

To learn more about SOTA Cloud®, visit: www.sotaimaging.com/sota-cloud

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Carestream Health notes twenty-seven of the patents were awarded by the U.S. Patent and Trademark Office; an additional 43 patents were received in European and Asian countries.
According to an Insightec study, patients experienced significant reductions in upper limb tremor, tremor-related disability, and quality of life. The most common intraprocedural adverse events included dizziness, headache, nausea, and vomiting, which all resolved. Post-procedural adverse events included paraesthesia and gait disturbance, which were often transient or resolved within 12 months.
Chris Landon, Business Leader Image Guided Therapy Devices at Philips: “IVUS is a technology that has demonstrated an ability to both support safer procedures for patients and procedural staff alike including reductions in radiation exposure. As the global leader in IVUS solutions, we are grateful for the rigorous multidisciplinary approach to developing expert consensus on the value of IVUS and we look forward to working with all stakeholders to standardize the use of IVUS and reduce the barriers preventing utilization.”
"We are delighted to see our 3D solution CE-marked and available on the European market," says Ulrik Harrysson, CEO at SyntheticMR AB. "SyMRI 3D represents the next generation of quantitative MRI, offering unprecedented resolution and accuracy in brain imaging, revolutionizing the landscape of medical diagnostics."
Adrian Mendes, Perimeter's Chief Executive Officer, stated, "We believe this additional commercial placement within a major national healthcare system – representing the fifth unit placed with this existing customer network – demonstrates that surgeon end users, as well as other stakeholders within the broader healthcare system, see the value of our technology and are recommending it to their peers. Our aim is to make Perimeter's innovative technology the standard of care in cancer surgery."

By using this website you agree to accept Medical Device News Magazine Privacy Policy